Equine Amniotic Microvesicles and Their Anti-Inflammatory Potential in a Tenocyte Model in Vitro

Stem Cells and Development

Volumn 25, Issue 8, 2016, Pages 610-621

  Lange Consiglio, Anna ^a   Perrini, Claudia ^a   Tasquier, Riccardo ^a   Deregibus, Maria Chiara ^b   Camussi, Giovanni ^b   Pascucci, Luisa ^c   Marini, Maria Giovanna ^d   Corradetti, Bruna ^d   Bizzaro, Davide ^d   De Vita, Bruna ^e   Romele, Pietro ^f   Parolini, Ornella ^f   Cremonesi, Fausto ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^e SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^f Istituto Ospedaliero   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; GELATINASE B; INTERSTITIAL COLLAGENASE; LIPOPOLYSACCHARIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; COLLAGENASE;

AMNIOTIC MESENCHYMAL CELL; ANIMAL CELL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE CELL; CELL PROLIFERATION; CONDITIONED MEDIUM; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; EQUIDAE; GENE EXPRESSION; IMMUNOMODULATION; IN VITRO STUDY; INFLAMMATION; MEMBRANE MICROPARTICLE; MESENCHYME CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPERNATANT; TENDON CELL; AMNION; ANIMAL; CELL CULTURE; CYTOLOGY; HORSE; IMMUNOLOGY; MESENCHYMAL STROMA CELL; METABOLISM; MONONUCLEAR CELL; PHYSIOLOGY; SECRETION (PROCESS); TENDON; TENOCYTE;

AMNION; ANIMALS; CELL PROLIFERATION; CELL-DERIVED MICROPARTICLES; CELLS, CULTURED; COLLAGENASES; CULTURE MEDIA, CONDITIONED; HORSES; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MESENCHYMAL STROMAL CELLS; TENDONS; TENOCYTES;

EID: 84964894933     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2015.0348     Document Type: Article

References (38)

1. Dazzi F and NJ Horwood. (2007). Potential of mesenchymal stem cell therapy. Curr Opin Oncol 19:650-655.
2. Hwang NS, C Zhang, YS Hwang and S Varghese. (2009). Mesenchymal stem cell differentiation and roles in regenerative medicine. Wiley Interdiscip Rev Syst Biol Med 1: 97-106.
3. Satija NK, VK Singh, YK Verma, P Gupta, S Sharma, F Afrin, M Sharma, P Sharma, RP Tripathi and GU Gurudutta. (2009). Mesenchymal stem cell-based therapy: a new paradigm in regenerative medicine. J Cell Mol Med 13: 4385-4402.
4. Leung VY, D Chan and KM Cheung. (2006). Regeneration of intervertebral disc by mesenchymal stem cells: potentials, limitations, and future direction. Eur Spine J 15 Suppl 3:S406-S413.
5. Lange-Consiglio A, S Tassan, B Corradetti, A Meucci, R Perego, D Bizzaro and F Cremonesi. (2013). Investigating the potential of equine mesenchymal stem cells derived from amnion and bone marrow in equine tendon diseases treatment in vivo. Cytotherapy 10:1016-1023.
6. Lange-Consiglio A, D Rossi, S Tassan, R Perego, F Cremonesi and O Parolini. (2013). Conditioned medium from horse amniotic membrane-derived multipotent progenitor cells: immunomodulatory activity in vitro and first clinical application in tendon and ligament injuries in vivo. Stem Cell Dev 22:3015-3024.
7. Caplan AI and JE Dennis. (2006). Mesenchymal stem cells as trophic mediators. J Cell Biochem 98:1076-1084.
8. Huang YC, O Parolini and L Deng. (2013). The potential role of microvesicles in mesenchymal stem cell-based therapy. Stem Cells Dev 15:841-844.
9. Ratajczak J, K Miekus, M Kucia, J Zhang, R Reca, P Dvorak and MZ Ratajczak. (2006). Embryonic stem cellsderived microvesicles reprogram hematopoietic progenitors: Evidence for horizontal transfer of mRNA and protein delivery. Leukemia 20:847-856.
10. Camussi G, MC Deregibus, S Bruno, V Cantaluppi and L Biancone. (2010). Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int 78:838-848.
11. Théry C, M Ostrowski and E Segura. (2009). Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 9:581-593.
12. Mathivanan S, H Ji and RJ Simpson. (2010). Exosomes: extracellular organelles important in intercellular communication. J Proteomics 73:1907-1920.
13. György B, TG Szabó, M Pásztó i, Z Pál, P Misják, B Aradi, V László, E Pállinger, E Pap, et al. (2011). Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci 68:2667-2688.
14. Biancone L, S Bruno, MC Deregibus, C Tetta and G Camussi. (2012). Therapeutic potential of mesenchymal stem cell-derived microvesicles. Nephrol Dial Transplant 27: 3037-3042.
15. Bruno S, C Grange, MC Deregibus, RA Calogero, S Saviozzi, F Collino, L Morando, A Busca, M Falda, et al. (2009). Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol 20:1053-1067.
16. Zhang HC, XB Liu, S Huang, XY Bi, HX Wang, LX Xie, YQ Wang, XF Cao, J Lv, et al. (2012). Microvescicles derived from human umbilical cord mesenchymal stem cells stimulated by hypoxia promote angiogenesis both in vitro and in vivo. Stem Cells Dev 21:3289-3297.
17. Lange-Consiglio A, B Corradetti, D Bizzaro, M Magatti, L Ressel, S Tassan, O Parolini and F Cremonesi. (2012). Characterization and potential applications of progenitorlike cells isolated from horse amniotic membrane. J Tissue Eng Regen Med 6:622-635.
18. Schorey JS and S Bhatnagar. (2008). Exosome function: from tumor immunology to pathogen biology. Traffic 9: 871-881.
19. Morel O, F Toti, B Hugel and JM Freyssinet. (2004). Cellular microparticles: A disseminated storage pool of bioactive vascular effectors. Curr Opin Hematol 11:156-164.
20. Deregibus MC, V Cantaluppi, R Calogero, M Lo Iacono, C Tetta, L Biancone, S Bruno, B Bussolati and G Camussi. (2007). Endothelial progenitor cell-derived microvescicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood 110:2440-2448.
21. Cocucci E, G Racchetti, P Podini and J Meldolesi. (2007). Enlargeosome traffic: exocytosis triggered by various signals is followed by endocytosis, membrane shedding or both. Traffic 8:742-757.
22. Dowling BA, AJ Dart and DR Hodgson. (2000). Superficial digital flexor tendonitis in the horse. Equine Vet J 32: 369-378.
23. Traub-Dargatz JL, MD Salman and JL Voss. (1991). Medical problems of adult horses, as ranked by equine practitioners. J Am Vet Res 198:1745-1747.
24. Prasanna SJ, D Gopalakrishnan, SR Shankar, AB Vasandan. (2010). Pro-inflammatory cytokines, IFN-g and TNFa, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS One 5:1-16.
25. Sternlicht MD and Z Werb. (2001). How matrix metalloproteinases regulate cell behavior. Ann Rev Cell Dev Biol 17:463-516.
26. Mott JD and Z Werb. (2004). Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 16:558-564.
27. Nomura M, Y Hosaka and Y Kasashima. (2007). Active expression of matri metalloptoinase-13 mRNA in Granulation Tissue of Equine Superficial Digital Flexor Tendinitis. J Vet Med Sci 69:637-639.
28. deLaat MA, MT Kyaw-Tanner, AR Nourian, CM McGowan, MN Sillence and CC Pollitt. (2011). The developmental and acute phases of insulin-induced laminitis involve minimal metalloproteinase activity. Vet Immunol Immunopathol 140:275-281.
29. Karousou E, M Ronga, D Vigetti, A Passi and N Maffulli. (2008). Collagens, proteoglycans, MMP-2, MMP-9 and TIMPS in human Achilles tendon rupture. Clin Orthop Relat Res 466:1577-1582.
30. Del Fattore A, R Luciano, L Pascucci, BM Goffredo, E Giorda, M Scapaticci, A Fierabracci and M Muraca. (2015). Immunoregulatory effects of mesenchymal stem cellderived extracellular vesicles on T lymphocytes. Cell Transplant 24:2615-2627.
31. Magatti M, S De Munari, E Vertua, L Gibelli, G Wengler and O Parolini. (2008). Human amnion mesenchyme harbors cells with allogeneic T-cell suppression and stimulation capabilities. Stem Cells 26:182-192.
32. Engela AU, CC Baan, FJ Dor, W Weimar and MJ Hoogduijn. (2012). On the interactions between mesenchymal stem cells and regulatory T cells for immunomodulation in transplantation. Front Immunol 3:126.
33. Nauta AJ and WE Fibbe. (2007). Immunomodulatory properties of mesenchymal stromal cells. Blood 110:3499-3506.
34. Galderisi U and A Giordano. (2014). The gap between the physiological and therapeutic roles of mesenchyma stem cells. Med Res Rev 34:1100-1126.
35. Aggarwal S and MF Pittenger (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105:1815-1822.
36. Chabannes D, M Hill, E Merieau, J Rossignol, R Brion, JP Soulillou, I Anegon and MC Cuturi. (2007). A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood 110:3691-3694.
37. Selmani Z, A Naji, I Zidi, B Favier, E Gaiffe, L Obert, C Borg, P Saas, P Tiberghien, et al. (2008). Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4 + CD25highFOXP3 + regulatory T cells. Stem Cells 26:212-222.
38. Rossi D, S Pianta, M Magatti, P Sedlmayr and O Parolini. (2012). Characterization of the conditioned medium from amniotic membrane cells: prostaglandins as key effectors of its immunomodulatory activity. PLoS One 7:e46956.